Platinum-based chemotherapy, such as carboplatin, is highly effective in BRCA1/2-mutated or HRD tumours, but resistance can develop through BRCA1/2 reversion mutations that restore HRR or epigenetic silencing of pro-apoptotic genes like MLH1 [43,44]. Here, BRCA1 is linked to neoplasm.